Search Results - "Toal, Martin"

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis by Polman, Chris H, O'Connor, Paul W, Havrdova, Eva, Hutchinson, Michael, Kappos, Ludwig, Miller, David H, Phillips, J. Theodore, Lublin, Fred D, Giovannoni, Gavin, Wajgt, Andrzej, Toal, Martin, Lynn, Frances, Panzara, Michael A, Sandrock, Alfred W

“…This placebo-controlled, randomized trial of patients with relapsing multiple sclerosis demonstrated benefits of natalizumab (an α 4 integrin antagonist) in…”
Get full text

Industry sponsored bias: NICE may be biased too by Toal, Martin J

Get full text

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study by Cortes, Jorge, Prof, Feldman, Eric, Prof, Yee, Karen, MD, Rizzieri, David, MD, Advani, Anjali S, MD, Charman, Anthony, PhD, Spruyt, Richard, BSc, Toal, Martin, FFPM, Kantarjian, Hagop, Prof

“…Summary Background Tosedostat is a novel oral aminopeptidase inhibitor with clinical activity in a previous phase 1–2 study in elderly patients with relapsed…”
Get full text

The BMJ, take heed: almost all studies have some degree of bias by Toal, Martin

“…In the section on cost effectiveness of initial drug treatment in Parkinson's disease, Muzerengi and Clarke say that health economic studies on drugs for…”
Get full text

Phase 1 and preclinical profiling of ESM‐HDAC391, a myeloid‐targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia by Furze, Rebecca C., Molnar, Judit, Parr, Nigel J., Ahmad, Faiz, Henry, Yvette, Howe, David, Singh, Rajendra, Toal, Martin, Bassil, Anna K., Bernard, Sharon G., Davis, Robert P., Gibson, Adele, Maller, N. Claire, Sharp, Catriona, Tough, David F., Prinjha, Rab K., Lewis, Huw D.

“…Aims To improve the tolerability and therapeutic application of histone deacetylase inhibitors (HDACi), by application of an esterase‐sensitive motif (ESM), to…”
Get full text

A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors by BANERJI, Udai, VAN DOORN, Leni, HOOFTMAN, Leon, DE BONO, Johann Sebastian, VERWEIJ, Jaap, ESKENS, Ferry Alm, PAPADATOS-PASTOS, Dionysis, KRISTELEIT, Rebecca, DEBNAM, Phillip, TALL, Matthew, STEWART, Adam, RAYNAUD, Florence, DAWN GARRETT, Michelle, TOAL, Martin

“…This clinical trial investigated the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profile of CHR-3996, a selective class I histone…”
Get full text

A phase I first‐in‐human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies by Ossenkoppele, Gert J., Lowenberg, Bob, Zachee, Pierre, Vey, Norbert, Breems, Dimitri, Loosdrecht, Arjan A., Davidson, Alan H., Wells, Graham, Needham, Lindsey, Bawden, Lindsay, Toal, Martin, Hooftman, Leon, Debnam, Phillip M.

“…Summary Tefinostat (CHR‐2845) is a monocyte/macrophage targeted histone deacetylase inhibitor (HDACi). This first‐in‐human, standard 3 + 3 dose escalating…”
Get full text

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukeaemia (OPAL): a randomized open-label phase 2 study by Cortes, Jorge, Feldman, Eric, Yee, Karen, Rizzieri, David, Advani, Anjali S., Charman, Anthony, Spruyt, Richard, Toal, Martin, Kantarjian, Hagop

Get full text

NICE may be biased too by Toal, Martin J

Get full text

Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia by Cortes, Jorge E., Feldman, Eric J, Yee, Karen, Rizzieri, David A., Advani, Anjali S., Charman, Anthony, Toal, Martin J., Kantarjian, Hagop M.

“…Abstract 767 Tosedostat is a novel oral inhibitor of the M1/17 family of aminopeptidases which induces an amino acid deprivation response that is selectively…”
Get full text

An Integrated Efficacy and Safety Analysis of Phase 1/2 Studies of Tosedostat, a Novel Aminopeptidase Inhibitor, as Monotherapy for Hematological Malignancies by Myint, Han, Campbell, Mary, Caldwell, Susan E, Wang, Lixia, Spuryt, Richard, Toal, Martin, Singer, Jack W

Get full text

NICE may be biased too by Toal, Martin J

“…[...]in the health economics of the use of [beta] interferons in relapsing-remitting multiple sclerosis, the effect on relapse prevention has little effect on…”
Get full text

509 The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia by Cortes, Jorge, Feldman, Eric, Yee, Karen, Toal, Martin, Richardson, Alison, Charman, Anthony, Flores, Nico

Get full text

Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis by Herndon, Robert M, Rudick, Richard A, Munschauer, Frederick E, Mass, Michele K, Salazar, Andres M, Coats, Michael E, Labutta, Robert, Richert, John R, Cohan, Stanley L, Genain, Claude, Goodkin, Donald, Toal, Martin, Riester, Katherine

“…An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFNβ-1a-Avonex) was conducted to evaluate the immunogenicity and…”
Get full text

Angiotensin converting enzyme (ACE) inhibitors in the treatment of heart failure in general practice in north Cumbria by Toal, Martin, Walker, Robert

“…Background: A great deal of research has demonstrated the benefits of treating patients with chronic heart failure with Angiotensin Converting Enzyme (ACE)…”
Get full text

Eight-year immunogenicity and safety of interferon beta-la-avonex® treatment in patients with multiple sclerosis by HERNDON, Robert M, RUDICK, Richard A, GOODKIN, Donald, TOAL, Martin, RIESTER, Katherine, MUNSCHAUER, Frederick E, MASS, Michele K, SALAZAR, Andres M, COATS, Michael E, LABUTTA, Robert, RICHERT, John R, COHAN, Stanley L, GENAIN, Claude

Get full text